Antonio Almeida

Professor Auxiliar

amalmeida@ics.lisboa.ucp.pt

Antonio Almeida

Professor Auxiliar

Bio

Antonio Almeida is currently head of department at Hospital da Luz, Lisbon, Portugal and also head of the hemato-oncology diagnostic laboratory at the Portuguese Institute of Oncology in Lisbon.

He was awarded his medical degree in 1993 from Cambridge University, UK, and completed his Specialist Training in Haematology in the UK in 2002. Following this Dr Almeida completed a clinical research fellowship through the Leukaemia Research Fund at Imperial College, London, and was awarded a PhD in 2007 for his work on the molecular characterization and targeted therapy for Inherited GPI Deficiency.

Dr Almeida’s research interests include myeloproliferative and myelodysplastic syndromes, focusing on epigenetic regulation of transcription regulation. He leads a Haematology Epigenetic research group and is the national principal investigator for several clinical trials in CML and MDS.

Dr Almeida has written book chapters and is the author of a range of articles published in journals including New England Journal of Medicine, Nature Medicine and Blood.

Publications

Paper

Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.

Almeida, A. (2020). Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.. Leukemia & lymphoma

Abertura da 6ª edição da Formação Avançada em Tecnologias de Apoio para a Inclusão

Reportagem SIC - Cuidados paliativos: apesar de existir mais profissionais com formação, número de equipas não é suficiente

Provas de Mestrado em Neuropsicologia

Antonio Almeida

Antonio Almeida

Bio

Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.

Acute myeloid leukemia in the older adults

Automated computer result reporting for haemoglobinopathy screening

Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

Bone involvement in sickle cell disease

Cell-type-specific transcriptional regulation of PIGM underpins the divergent hematologic phenotype in inherited GPl deficiency

Chapter 16 Inherited GPI deficiency

Clinical benefit of eculizumab in patients with no transfusion history in the International Paroxysmal Nocturnal Haemoglobinuria Registry

Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial

Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox

Clinical outcomes of 217 patients with acute erythroleukemia according to treatment type and line: A retrospective multinational study

Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study

Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective

Controlo transcricional de PIGM:mecanismo de expressão diferencial em células sanguíneas na insuficiência hereditária de GPI

Design and rationale of the QUAZAR lower-risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes a...

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes.

Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS

Epigenetic Alterations in Fanconi anaemia: Role in pathophysiology and therapeutic potential

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia.

Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia.

Evidence-Based Criteria for Tyrosine Kinase Inhibitor Interruption in Pregnancy.

Fludarabine-based stem cell transplantation protocol for Fanconi's anaemia in myelodysplastic transformation

Generalized skin reactions in patients with MDS and CMML treated with azacitidine: Effective management with concomitant prednisolone

Guideline-based indicators for adult patients with myelodysplastic syndromes.

HDAC8 overexpression in mesenchymal stromal cells from JAK2<sup>+</sup>myeloproliferative neoplasms: A new therapeutic target?

Hematology traning in Europe

Human invariant NKT cells are required for effective in vitro alloresponses

Hypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiency

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry.

Inherited glycosylphosphatidyl inositol deficiency: A treatable CDG

Less iron improves MDS haematopoiesis.

Modifying disease in CMML: Who responds to Azacitidine?

Monocytes as Endothelial Progenitor Cells (EPCs), Another Brick in the Wall to Disentangle Tumor Angiogenesis.

Negative MR<sup>4·0</sup> chronic myeloid leukaemia and its possible implications for treatment-free remission.

Neonatal screening for haemoglobinopathies: The results of a 10-year programme in an English Health Region

Neonatal screening for sickle cell disorders

New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective

Optimizing treatments in rare diseases: Will our evidence come from registry data?

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes

Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents

Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+)

Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)

Recommendations for diagnosis, treatment and monitoring of chronic myeloid leukemia | Recomendações para o diagnóstico, tratamento e monitorização da leucemia mielóide crónica

Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatme...

Should more MDS patients be treated with immune-suppression?

Spontaneous Tumor Lysis Syndrome: A Rare Presentation in Plasmablastic Lymphoma

Targeted therapy for inherited GPI deficiency

The Activation of Endothelial Cells Relies on a Ferroptosis-Like Mechanism: Novel Perspectives in Management of Angiogenesis and Cancer Therapy

The bone marrow-mediated protection of myeloproliferative neoplastic cells to vorinostat and ruxolitinib relies on the activation of JNK and PI3K Signalling Pathways

The use of recombinant factor VIIa in children with inherited platelet function disorders.

Therapeutic challenges in childhood sickle cell disease Part 1: Current and future treatment options

Therapeutic challenges in childhood sickle cell disease. Part 2: A problem-orientated approach

Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event.

Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event.

Treatment of acute erythroleukemia with Azacitidine: A case series

Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature review

Unusual presentation of factor XIII deficiency

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

Vorinostat Induces Apoptosis and Differentiation in Myeloid Malignancies: Genetic and Molecular Mechanisms

Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms